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1. Introduction 
Neuropathic pain can be caused by a number of different diseases such as diabetes mellitus 
(DM), herpes zoster, Human Inmunodeficiency virus (HIV), cancer or secondary to 
treatment i.e. radiotherapy, chemotherapy or surgery. Alterations in the nerve pathways 
such as trigeminal or nerve roots can lead to pain.  
Another study from Mayo Clinic reported neuropathic pain in 66% of insulin-dependent 
diabetic patients and 59% in non-insulin dependent diabetic patients (Davies 2006). 
Epidemiological study in Minnesota reported an annual incidence of postherpetic neuralgia 
to be 11.6 per 100,000 people per year, similar to seen in UK with a lifetime incidence of 
70/100, 000. (Dyck 1993) 
Traditionally, neuropathic pain has been classified into peripheral and central, taking into 
account the anatomical location of the lesion or anatomical dysfunction. The current 
definition of neuropathic pain indicates that it is "pain that arises as a direct result of an 
injury or illness affecting the somatosensory system" (Treede 2008). Several recent studies 
have shown that neuropathic pain may adversely affect the overall quality of life including 
physical and emotional health (Oster 2005), which are associated with significant social costs 
(O ' Connor 2009). 
Neuropathic pain is associated with suffering, disability, decreased quality of life and 
increased costs. The exact prevalence is unknown. German Studies state that 37% of patients 
with chronic low back pain have predominantly neuropathic pain, in terms of painful 
diabetic neuropathy occurs in 16% in patients with diabetes in the UK, one third of these 
patients had never received Treatment for this type of pain. In the United States two-thirds 
of patients with painful diabetic neuropathy workers reported absence from work or 
decreased productivity due to pain and only one fifth of these employees were satisfied 
with their treatment prescribed analgesic (Bouhassira 2008).  
Of the various etiologies of neuropathic pain DM needs the most attention due to the 
increasing number of patients expected by 2025. It is estimated that the present number of 
246 million people worldwide will increase to 380 million especialy in developing countries. 
Though estimated 80% of these patients live in developing or under developed countries 
only 20% increased will be in the budget to treat this condition (Walters1992/Davies 2006). 
These epidemiological data support that neuropathic pain has severe impact on the 
economic, social and emotional aspects of patient population. 
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Neuropathic pain is considered a diagnostic and therapeutic challenge because it can often be 
the result of a diverse group of diseases, which differ in etiology, and symptomatology. In 
some disorders the clinical picture may or may not be related to the anatomical distribution. 
Although a primary goal of pain management is to relieve pain using a single agent, the 
reality is that monotherapy rarely provides adequate relief from chronic neuropathic pain. 
In these complex and refractory situations, combination therapy using two or more agents 
with synergistic mechanisms of action (eg, gabapentin + tramadol) is frequently necessary. 
In clinical practice, some patients begin to respond to a particular monotherapy, but often 
are restricted by dose-related side effects. In such cases, combination therapy with two or 
more agents with different modes of action at suboptimal doses may provide the additive 
effects or even synergistic effects necessary for optimal pain relief without compromising 
the side-effect profile of each agent. (NEJ 2005) 
2. Clinical efficacy 
Under the umbrella of the IASP (International Association for Study of Pain) a chapter or 
group with special interest in neuropathic pain (NeuPSIG) held a consensus to develop 
evidence-based guidelines for the pharmacological treatment of neuropathic pain that took 
into account the clinical efficacy, adverse effects, the impact on quality of life related to 
health, and costs. (Connor 2009) 
Three classes of drugs were recommended as first line of treatment for neuropathic pain: 
antidepressants, which inhibit both norepinephrine and serotonin reuptake (tricyclic 
antidepressants and selective inhibitors and inhibitors of norepinephrine reuptake [SNRIs]), 
the ligand calcium channel blockers, gabapentin and pregabalin, and topical lidocaine 
(lidocaine patch 5%). 
Opioids and tramadol are recommended as second-line treatment in generalexcept in 
certain specific clinical situations in which they can be considered for first-line use. 
Other medications are considered third-line therapy. The guidelines recognize that an 
effective drug combination for neuropathic pain may provide greater analgesia than the use 
of single drugs (monotherapy) (NEJ 2005), although this therapy can often be associated 
with more side effects or risk of drug interactions. However, the combination therapy was 
incorporated into a management strategy for patients with partial response to treatment 
with first-line drugs. 
Four steps should be performed that may require treatment, dose adjustment or additional 
monitoring of therapy 
Step 1.  
- Establishing the diagnosis of neuropathic pain. 
- Assess pain 
- Establish and treat the cause of neuropathic pain. 
- Identify relevant comorbidities (eg, heart, kidney or liver disease, depression) that may 
require treatment or dose adjustment or additional monitoring of therapy 
- Explain the diagnosis and treatment plan for the patient and set realistic expectations 
Step 2.  
- Initiate therapy for the disease causing neuropathic pain. 
- Start the treatment of symptoms with one or more of the following: 
A ligand calcium channel alpha 2-delta (gabapentin) 
- For patients with peripheral neuropathic pain localized topical lidocaine used alone or 
in combination with one of the other first-line therapies 
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- For patients with acute neuropathic pain, Neuropathic pain due to cancer, 
exacerbations or episodes of severe pain and / or when the system of pain relief during 
the assessment of a first-line drug to an effective dose is required, opioid analgesics or 
tramadol may be used alone or in combination with one of the first-line therapies 
- Assess the patient for non-pharmacological treatments and to initiate, if necessary 
Step 3.  
- Reassess the pain and often assess the quality of life related to health. 
- If pain relief is adequate (for example, the average pain reduced to ≤ 3 / 10) and 
tolerable side effects, continue the treatment. 
- If there is partial relief of pain (for example, the average is still ≥ 4 / 10) after 
appropriate treatment, add one of the other four first-line drugs. 
- If no or inadequate pain relief (eg, reduction of <30%) after appropriate treatment 
should be changed to an alternative first-line drug 
Step 4.  
- If the tests of first-line drugs alone and in combination fail, consider the second-and 
third-line and / or referral to a pain specialist (2009) 
Importantly, the doses used (start, qualifications and maximum) and the duration of clinical 
trials are appended in the table below. 
The duration of the trials with the use of gabapentin was 3-10 weeks with 4 weeks use of 
tramadol. 
3. Treatment of neuropathic pain and pharmacological classes 
3.1 Antidepressants 
TCAs are often listed as first-line drugs for neuropathic pain. Typically, this class of agents 
is separated into two categories based on their chemical structure: tertiary and secondary 
amines. TCAs appear to affect pain transmission via multiple mechanisms including 
reuptake inhibition of both serotonin and norepinephrine at spinal cord receptor sites, 
including projections to the brain stem and dorsal horn nuclei. It has been postulated that 
the tertiary agents maintain a more balanced chemical profile, providing inhibition of both 
serotonin and norepinephrine. In contrast, the secondary amines appear to provide more 
reuptake inhibition of norepinephrine. The analgesic properties of TCAs appear to be 
independent of their antidepressant properties. Other possible mechanisms of action 
include: alpha-adrenergic blockade; anticholinergic effects; antihistaminic effects; reuptake 
inhibition of dopamine; effects on gamma-aminobutyric acid (GABA)-B and adenosine; 
potassium, calcium and, most importantly, sodium channel blockade; N-methyl-D-aspartic 
acid (NMDA)-receptor antagonism. 
The secondary amines (eg, desipramine and nortriptyline) appear to be as effective as the 
tertiary agents (eg, imipramine and amitriptyline) as analgesics in neuropathic pain and 
produce markedly fewer side effects This favorable side-effect profile makes secondary 
amine TCAs more clinically appropriate for many patients. 
3.2 Anticonvulsants 
As with epilepsy, the hallmark characteristic of neuropathic pain is thought to be neuronal 
hyperexcitability. Some of the known mechanisms of action of anticonvulsants include 
blockade of the membrane sodium currents, effects on calcium conductance, activation of 
the gamma-aminobutyric acid (GABA) inhibitory system by direct or indirect means, and 
reduction of the activity of the excitatory neurotransmitter glutamate. The net result is the 
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depression of synaptic transmission and the elevation of the threshold for repetitive firing of 
nociceptive neurons, as well as a reduction in discharges of the dorsal root ganglion cells. 
To date, only five agents have been evaluated in randomized double-blind clinical trials. 
These are carbamazepine, gabapentin, lamotrigine, phenytoin, and pregabalin. Of these, 
carbamazepine and phenytoin require intensive monitoring of serum levels and maintain a 
fairly extensive adverse effect profile. Lamotrigine use is limited by a risk of Stevens–Johnson 
syndrome and other serious dermatological adverse events. Gabapentin produces markedly 
fewer adverse effects than many other anticonvulsants, and does not require blood tests. 
Gabapentin has recently been shown to be an effective treatment option for both DPN and 
PHN in two large multicenter, randomized, double-blind, placebo-controlled, parallel group 
trials. Gabapentin was also compared to amitriptyline in a small-scale prospective, 
randomized, double-blind, double-dummy, crossover study in DPN. Although both drugs 
provided analgesia, no significant difference was shown between gabapentin and 
amitriptyline with respect to pain scores or global pain assessment. The authors concluded 
that gabapentin is an effective alternative to amitriptyline for treatment of DPN pain, but 
could not be recommended over amitriptyline due to cost. 
The most common side effects of gabapentin are drowsiness, somnolence, and generalized 
fatigue. These side effects are usually transient, lasting an average of 2 to 3 weeks. Treatment 
should be initiated at 300 mg at bedtime, with a test dose of 100 mg at bedtime for elderly 
patients. The dose is then increased by 300 mg every 3 to 5 days, until the patient has adequate 
pain relief. The median effective daily dose ranges between 900 and 1800 mg, although some 
patients respond to daily doses as low as 100 mg and others require 3600 mg. Gorson and 
colleagues reported that doses less than 900 mg per day (300 mg TID) are either ineffective or 
only minimally effective for the treatment of painful diabetic neuropathy. The average age of 
the patients evaluated in this report was 62 years. Because of its short half-life, gabapentin 
should be administered on a TID schedule. The drug is excreted unchanged by the kidneys, 
with clearance directly proportional to creatinine clearance. Therefore, dosage reduction may 
be needed in patients with renal impairment. As a result of the lack of drug–drug interactions, 
gabapentin may be an attractive agent for patients receiving multiple medications. 
Stacey (2005) identified several randomized, double-blind clinical trials (level 2 evidence) 
demonstrating that gabapentin had significantly greater efficacy than placebo in PHN (at 
1800 to 3600 mg/day) and DPN (900 to 3600 mg). In DPN, gabapentin showed comparable 
efficacy to amitriptyline. Controlled clinical trials suggest that carbamazepine (100 to 4000 
g/day) is effective in TGN and DPN, but not PHN or central pain (all level 2 evidence). 
Compared to the first-generation anticonvulsants, gabapentin has a more favorable safety 
and tolerability profile. Pregabalin (300 or 600 mg/day) also appears to be effective in some 
types of neuropathic pain, with level 2 evidence indicating that 50% of patients with PHN 
achieved a decrease in pain of 50% or more. Sodium valproate has demonstrated efficacy in 
painful DPN (level 2 evidence), but the evidence for other anticonvulsants (levetiracetam, 
oxcarbazepine, topiramate, zonisamide) in the treatment of neuropathic pain was not as 
good. These results were in accordance with those from earlier studies. Anticonvulsants are 
thought to hold significant promise in the treatment of CRPS. Carbamazepine has a 
traditional and perhaps clinically important place in this indication, and gabapentin holds 
significant promise (level 4 evidence). 
3.3 Opioids and tramadol 
Opioid agonists work by mimicking the activity of enkephalins and endorphins in the 
central descending pathways of the pain-processing loop. By binding to mu-opioid 
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receptors in the central nervous system, opioid agonists dampen neuronal excitability and 
elicit pain relief. Despite concerns regarding the efficacy of opioids in neuropathic pain, several 
double-blind RCTs (level 2 evidence) have demonstrated that oxycodone, morphine, and 
methadone can be modestly effective in PHN, DPN, phantom limb pain, and other types of 
neuropathic pain. A recent review demonstrated that opioids had significant efficacy over 
placebo for neuropathic pain in intermediate-term studies. Although reported adverse events 
with opioids were common, they were not life-threatening. When compared to treatment with 
TCAs, opioids were as effective but resulted in a greater number of dropouts. Nevertheless, 
patients who finished the study preferred treatment with opioids over TCA. 
Tramadol is a centrally acting agent with a weak affinity for mu-opioid receptors and weak 
reuptake inhibition of the neurotransmitters norepinephrine and serotonin. It has shown 
utility in a variety of pain syndromes, most notably neuropathic pain. Treatment should 
generally be initiated at a dose of 50 mg daily and increased by 50 mg increments every 3 to 
5 days. Adverse events increase with more rapid dose titration. Effective daily doses range 
between 100 and 400 mg, administered in divided doses four times daily. The most common 
adverse effects of tramadol are dizziness, vertigo, nausea, constipation, headache, and 
somnolence. In addition, patients with a history or potential for seizure activity should 
avoid use of this agent. 
3.4 Topical agents 
Topical agents work locally, directly at the site of application, with minimal systemic effects. 
Lidocaine, like other local anesthetics, seems to act through inhibition of voltage-gated 
sodium channels. Capsaicin is thought to elevate the pain threshold in which it is applied 
through depletion of the nociceptive neurotransmitter, substance P, from the terminals of 
unmyelinated C fibers. It also causes degeneration of substance P-positive epidermal nerve 
fibers. Ketamine works through antagonism of the NMDA receptors and clonidine is 
thought to act at the presynaptic alpha-2 adrenergic receptors, subsequently inhibiting 
release of norepinephrine. 
The evidence supporting the 5% lidocaine patch for the treatment of neuropathic pain is 
strong. The lidocaine patch is effective in PHN (level 2 evidence), with minimal risk of drug 
interactions or systemic adverse effects. However, the current approved dose of 12-hour 
on/12-hour off was found to be insufficient for some patients. The lidocaine patch also has 
shown efficacy in DPN (level 2 evidence), with the number needed to treat in some studies 
comparing favorably to those of other treatments for neuropathic pain. Complete or some 
pain relief has been noted in patients with myofascial pain (two-thirds of whom had lower 
back pain) and in those with lower back pain. Both types of pain may result, in part, from 
neuropathic mechanisms. The lidocaine patch also may be useful in the treatment of CRPS. 
Capsaicin cream (0.075%) was evaluated in several clinical studies for DPN and PHN (both 
level 2 evidence). Although results were inconsistent, clinical experience suggests it may 
occasionally be effective in individual circumstances. Capsaicin also has partial efficacy in 
CRPS (level 3 evidence). Level 3 evidence was noted for the efficacy of ketamine gel in the 
treatment of neuropathic pain. 
3.5 Anesthetics for systemic use 
Abnormal electrical activity in injured nerves and neuromas is partly generated by 
abnormal accumulation of sodium channels. Therefore, a sodium channel-blocking agent 
may help to relieve neuropathic pain. Such medications include intravenous lidocaine 
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(which also depresses C-fiber polysynaptic evoked activity and thus suppresses dorsal horn 
neurons to the C-fiber input), oral mexiletine (which has a similar mode of action to 
lidocaine), and oral tocainamide. The GABAergic system in the spinal cord also plays a 
pivotal role in modulating pain control and as a result, baclofen (a GABA-B-receptor 
agonist) has been shown to be effective for neuropathic pain. 
 
 
Fig. 1. Combined number-needed-to-treat (NNT) values for various drug classes in all 
central and peripheral neuropathic pain conditions (not including trigeminal neuralgia, 
cancer-related neuropathic pain, or radiculopathies).The circle sizes indicate the relative 
number (given in parentheses) of patients who received active treatment drugs in trials for 
which dichotomous data were available. It is important to note that because studies on 
tricyclic antidepressants (TCAs), selective serotonin reuptake inhibitors (SSRIs), and opioids 
are mainlycrossover trials and studies on SNRIs and gabapentin or pregabalin are mainly 
parallel-group design studies, a direct comparison of NNT values across drug classes cannot 
be made. Adapted from Finnerup et al. The evidence for pharmacological treatment of 
neuropathic pain. Pain 2010;150:573–81. 
Abbreviations: BTX-A = botulinum toxin A; ns = absolute risk difference not signifi cant; 
SNRIs = mixed serotoninnorepinephrine reuptake inhibitors. 
Mexilitene, an orally available lidocaine congener antiarrhythmic, has been evaluated in 
several double-blind clinical trials for treatment of painful diabetic neuropathy. Only one of 
these trials demonstrated significant pain relief with mexilitene, and even then only limited 
nighttime pain relief with high doses (675 mg per day). Mexilitene is not a benign drug, and 
as such has a less than favorable adverse effect profile. Common adverse effects include 
chest pain, dizziness, gastrointestinal disturbances, palpitations, and tremor. As with other 
antiarrhythmics, mexilitene may worsen existing arrhythmia. The daily effective dose 
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ranges between 450 and 675 mg, usually administered on a thrice daily schedule. As a 
function of its questionable efficacy and its toxicity, mexilitene should be considered an 
option only when other measures have failed. 
In clinical practice, a combination of two or more drugs is often needed to achieve 
satisfactory pain relief, although there have been few trials done to support this clinical 
observation. However, combination therapy with gabapentin and extended-release 
morphine in patients with postherpetic neuralgia or painful diabetic neuropathy and 
extended-release morphine and pregabalin in different neuropathic pain síndromes 
(neuropathic back pain, postherpetic neuralgia, radiculopathy, painful diabetic neuropathy) 
had higher pain relief with lower doses compared with administration of one drug alone. 
These results have also been confirmed for the combination of nortriptyline and gabapentin, 
as well as for pregabalin and topical lidocaine, in patients with painful diabetic neuropathy 
and postherpetic neuralgia. Taken together, these results substantiate the usefulness of 
combination therapy in patients with neuropathic pain. 
4. Conclusions 
Although a primary goal of pain management is to relieve pain using a single agent, the 
reality is that monotherapy rarely provides adequate relief from chronic neuropathic pain. 
In these complex and refractory situations, combination therapy using two or more agents 
with synergistic mechanisms of action (eg, gabapentin + lamotrigine or tramadol + 
gabapentin) is frequently necessary. In clinical practice, some patients begin to respond to a 
particular monotherapy, but often are restricted by dose-related side effects. In such cases, 
combination therapy with two or more agents with different modes of action at suboptimal 
doses may provide the additive effects or even synergistic effects necessary for optimal pain 
relief without compromising the side-effect profile of each agent. However, it is essential 
that a careful patient history is taken before initiating a polypharmacy regimen. 
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